New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
07:09 EDTRTRXRetrophin raises FY14 revenue view to $19M-$21M from $10M-$12M
One estimate $11M. Raises FY15 revenue view to $35M-$40M from $19M-$21M, one estimate $20M. Retrophin CEO Martin Shkreli said, “Reimbursement of Chenodal has remained robust, and initial efforts to find undiagnosed cerebrotendinous xanthomatosis patients are promising. We have raised our guidance for 2014 and 2015 revenue accordingly. We are very comfortable with our current cash balance and future obligations. The success of Chenodal significantly reduces our cash needs and may propel the company to profitability in the near-term. As such, we have no need or desire to explore a dilutive equity offering unless it is accompanied by an accretive and strategic acquisition. Retrophin remains opportunistic with respect to M&A and has strong access to both debt and equity capital.”
News For RTRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 22, 2015
09:26 EDTRTRXRetrophin management to meet with Leerink
Subscribe for More Information
May 15, 2015
10:29 EDTRTRXAmerican Urological Association to hold an annual meeting
Subscribe for More Information
10:01 EDTRTRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:18 EDTRTRXRetrophin initiated with an Outperform at Avondale
Subscribe for More Information
May 11, 2015
16:31 EDTRTRXRetrophin reports Q1 EPS (4c) vs. (75c) last year
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use